Advances in targeted therapies II GUEST EDITORS, F C BREEDVELD, J R KALDEN, and J S SMOLEN Ann Rheum Dis 2000; 59 (Supplement 1 ): i. doi:10.1136/ard.59.suppl_1.i0 [Extract] [Full text] [Correction to Supplement] [Request Permissions]

	Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000) D E FURST, F C BREEDVELD, G R BURMESTER, J J CROFFORD, P EMERY, M FELDMANN, J R KALDEN, A F KAVANAUGH, E C KEYSTONE, L G KLARESKOG, P E LIPSKY, R N MAINI, A S RUSSELL, D L SCOTT, J S SMOLEN, L B A VAN DE PUTTE, T L VISHER, and M H WEISMAN Ann Rheum Dis 2000; 59 (Supplement 1 ): i1-i2. doi:10.1136/ard.59.suppl_1.i1 [Extract] [Full text] [PDF] [Request Permissions]
	Post-transcriptional regulation of tumour necrosis factor production Paul Anderson Ann Rheum Dis 2000; 59 (Supplement 1 ): i3-i5. doi:10.1136/ard.59.suppl_1.i3 [Extract] [Full text] [PDF] [Request Permissions]
	Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-B Bharat B Aggarwal Ann Rheum Dis 2000; 59 (Supplement 1 ): i6-i16. doi:10.1136/ard.59.suppl_1.i6 [Abstract] [Full text] [PDF] [Request Permissions]
	Targeting interleukin 18 with interleukin 18 binding protein Charles A Dinarello Ann Rheum Dis 2000; 59 (Supplement 1 ): i17-i20. doi:10.1136/ard.59.suppl_1.i17 [Abstract] [Full text] [PDF] [Request Permissions]
	Anti-interleukin 6 receptor antibody treatment in rheumatic disease Norihiro Nishimoto, Tadamitsu Kishimoto, and Kazuyuki Yoshizaki Ann Rheum Dis 2000; 59 (Supplement 1 ): i21-i27. doi:10.1136/ard.59.suppl_1.i21 [Abstract] [Full text] [PDF] [Request Permissions]
	Clinical outcome measures in rheumatoid arthritis Piet L C M van Riel and Anke M van Gestel Ann Rheum Dis 2000; 59 (Supplement 1 ): i28-i31. doi:10.1136/ard.59.suppl_1.i28 [Extract] [Full text] [PDF] [Request Permissions]
	Efficacy and toxicity of old and new disease modifying antirheumatic drugs Peter Tugwell, Vivian Welch, Maria Suarez-Almazor, Beverley Shea, and George Wells Ann Rheum Dis 2000; 59 (Supplement 1 ): i32-i35. doi:10.1136/ard.59.suppl_1.i32 [Extract] [Full text] [PDF] [Request Permissions]
	Which post-marketing database and studies does EMEA require Gottfried Kreutz and Leng Heng Ann Rheum Dis 2000; 59 (Supplement 1 ): i36-i37. doi:10.1136/ard.59.suppl_1.i36 [Extract] [Full text] [PDF] [Request Permissions]
	The role of national agencies in the managed introduction of new drugs for arthritis Katrina Simister Ann Rheum Dis 2000; 59 (Supplement 1 ): i38-i40. doi:10.1136/ard.59.suppl_1.i38 [Abstract] [Full text] [PDF] [Request Permissions]
	Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update Mark W Davis, Ulrich Feige, Alison M Bendele, Steven W Martin, and Carl K Edwards, III Ann Rheum Dis 2000; 59 (Supplement 1 ): i41-i43. doi:10.1136/ard.59.suppl_1.i41 [Extract] [Full text] [PDF] [Request Permissions]
	Update on D2E7: a fully human anti-tumour necrosis factor monoclonal antibody Joachim Kempeni Ann Rheum Dis 2000; 59 (Supplement 1 ): i44-i45. doi:10.1136/ard.59.suppl_1.i44 [Extract] [Full text] [PDF] [Request Permissions]
	Etanercept (Enbrel): update on therapeutic use George Spencer-Green Ann Rheum Dis 2000; 59 (Supplement 1 ): i46-i49. doi:10.1136/ard.59.suppl_1.i46 [Abstract] [Full text] [PDF] [Request Permissions]
	The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function Francis Ka-Ming Chan Ann Rheum Dis 2000; 59 (Supplement 1 ): i50-i53. doi:10.1136/ard.59.suppl_1.i50 [Abstract] [Full text] [PDF] [Request Permissions]
	Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFB in tumour necrosis factor production Brian M J Foxwell, Jan Bondeson, Fionula Brennan, and Marc Feldmann Ann Rheum Dis 2000; 59 (Supplement 1 ): i54-i59. doi:10.1136/ard.59.suppl_1.i54 [Abstract] [Full text] [PDF] [Request Permissions]
	Biological role of interleukin 1 receptor antagonist isoforms William P Arend and Carla J Guthridge Ann Rheum Dis 2000; 59 (Supplement 1 ): i60-i64. doi:10.1136/ard.59.suppl_1.i60 [Abstract] [Full text] [PDF] [Request Permissions]
	The role of angiogenesis in rheumatoid arthritis: recent developments Alisa Erika Koch Ann Rheum Dis 2000; 59 (Supplement 1 ): i65-i71. doi:10.1136/ard.59.suppl_1.i65 [Extract] [Full text] [PDF] [Request Permissions]
	The final pathogenetic steps in focal bone erosions in rheumatoid arthritis Steven R Goldring Ann Rheum Dis 2000; 59 (Supplement 1 ): i72-i74. doi:10.1136/ard.59.suppl_1.i72 [Extract] [Full text] [PDF] [Request Permissions]
	Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor Richard O Williams, Marc Feldmann, and Ravinder N Maini Ann Rheum Dis 2000; 59 (Supplement 1 ): i75-i80. doi:10.1136/ard.59.suppl_1.i75 [Extract] [Full text] [PDF] [Request Permissions]
	Arguments for interleukin 1 as a target in chronic arthritis Wim B van den Berg Ann Rheum Dis 2000; 59 (Supplement 1 ): i81-i84. doi:10.1136/ard.59.suppl_1.i81 [Abstract] [Full text] [PDF] [Request Permissions]
	Treatment of spondyloarthropathies with antibodies against tumour necrosis factor : first clinical and laboratory experiences Jürgen Braun, Jian Xiang, Jan Brandt, Hardy Maetzel, Hildrun Haibel, Peihua Wu, Siegfried Kohler, Martin Rudwaleit, Stefanie Siegert, Andreas Radbruch, Andreas Thiel, and Joachim Sieper Ann Rheum Dis 2000; 59 (Supplement 1 ): i85-i89. doi:10.1136/ard.59.suppl_1.i85 [Extract] [Full text] [PDF] [Request Permissions]
	Activation of cytokines as a mechanism of disease progression in heart failure Biykem Bozkurt Ann Rheum Dis 2000; 59 (Supplement 1 ): i90-i93. doi:10.1136/ard.59.suppl_1.i90 [Extract] [Full text] [PDF] [Request Permissions]
	Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system Krzysztof W Selmaj Ann Rheum Dis 2000; 59 (Supplement 1 ): i94-i102. doi:10.1136/ard.59.suppl_1.i94 [Extract] [Full text] [PDF] [Request Permissions]
	Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis Michael H Schiff Ann Rheum Dis 2000; 59 (Supplement 1 ): i103-i108. doi:10.1136/ard.59.suppl_1.i103 [Abstract] [Full text] [PDF] [Request Permissions]
	Advances in interleukin 2 receptor targeted treatment John C Morris and Thomas A Waldmann Ann Rheum Dis 2000; 59 (Supplement 1 ): i109-i114. doi:10.1136/ard.59.suppl_1.i109 [Abstract] [Full text] [PDF] [Request Permissions]
	Jaks and Stats as therapeutic targets John J O'Shea, Roberta Visconti, Tammy P Cheng, and Massimo Gadina Ann Rheum Dis 2000; 59 (Supplement 1 ): i115-i118. doi:10.1136/ard.59.suppl_1.i115 [Abstract] [Full text] [PDF] [Request Permissions]
	Future prospects for anti-cytokine treatment Marc Feldmann, Jadwiga Miotla, Ewa Paleolog, Richard Williams, Anne-Marie Malfait, Peter Taylor, Fionula M Brennan, and Ravinder N Maini Ann Rheum Dis 2000; 59 (Supplement 1 ): i119-i122. doi:10.1136/ard.59.suppl_1.i119 [Abstract] [Full text] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.